Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention
Yıl: 2010 Cilt: 10 Sayı: 4 Sayfa Aralığı: 340 - 345 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention
Öz: Bu çalışmadaki amacımız primer perkütan koroner girişim (PKG) uygulanan ST elevasyonlu miyokart enfarktüsü hastalarında bir glikoprotein IIb/IIIa reseptör blokeri olan tirofibanın intrakoroner (İK) ve intravenöz (İV) bolus dozlarının klinik sonuçlar ve zirve kardiyak enzim seviyeleri açısından karşılaştırılmaktır. Yöntemler: Merkezimizde Mart 2006 ve Şubat 2007 tarihleri arasında primer PKG uygulanan 84 hasta retrospektif olarak incelendi. Hastalara 10 mcg/kg tirofiban bolus dozu İK veya İV yolla uygulandı ve 36 saat boyunca 0.15 mcg/kg/dk dozundan IV yolla devam edildi. İK gruptaki 36 hasta ve IV gruptaki 48 hasta zirve kardiyak enzim seviyeleri, hastane içindeki ve 6. aydaki majör istenmeyen kardiyak olay (ölüm, miyokardiyal enfarktüs, tekrarlayan revaskülarizasyon) oranları açısından karşılaştırıldı. İstatistiksel değerlendirmede Fisher’s test, Yates Ki-kare, eşleştirilmemiş Student t testi ve Mann-Whitney U testi kullanıldı. Bulgular: Kardiyovasküler risk profilleri ya da geçirilmiş kardiyak olaylar açısından iki grup arasında fark yoktu. Altı aylık takipte majör istenmeyen kardiyak olay oranları İV grupta %6.25 ve İK grupta ise %11.1 olarak saptandı (p=0.45). Her iki grupta zirve kardiyak fosfokinaz seviyeleri arasında istatistiksel bir fark saptanmadı (İV grupta 2657±2181 U/L ve İK grupta 2529±1929 U/L) (p=0.92). Sonuç: Primer PKG uygulanan ST elevasyonlu miyokart enfarktüsü hastalarında tirofiban bolus dozunun intrakoroner uygulanması majör istenmeyen kardiyak olay sıklığını intravenöz uygulamaya göre azaltmamıştır. İleride yapılacak ve daha yüksek intrakoroner bolus dozunun kullanıldığı prospektif çalışmalar bu konunun açıklanmasına ışık tutacaktır.
Anahtar Kelime: Konular:
Primer perkütan koroner girişim uygulanan hastalarda tirofibanın intrakoroner ve intravenöz bolus dozlarının karşılaştırılması
Öz: The purpose of this study was to compare the intravenous bolus dose of tirofiban with intracoronary bolus dose in primary percutaneous coronary intervention (PCI) with regard to in hospital and six months clinical outcomes and peak cardiac enzyme levels. Methods: We retrospectively examined 84 ST elevation myocardial infarction (STEMI) patients who underwent primary PCI from March 2006 to February 2007. All patients received the systemic bolus dose of tirofiban 10 mcg/kg either via intracoronary (IC) or intravenous (IV) route, followed by a 36 hours of IV infusion at 0.15 mcg/kg/min. Thirty six patients in IC group were compared with 48 patients in IV group in terms of peak cardiac enzyme levels, in-hospital and six months major adverse cardiac events (MACE) rates (death, myocardial infarction and repeat revascularization). Fisher’s exact test, Yates Chi-square, unpaired Student’s t-test and Mann-Whitney U test were used for statistical analysis. Results: There was no difference in cardiovascular risk profile or cardiac history between two groups. At six months the incidence of MACE was 6.25% in IV group and 11.1% in IC group (p=0.45). Peak cardiac phosphokinase (CPK) levels between IV and IC groups were also statistically non significant (2657±2181 U/L in IV group and 2529±1929 U/L in IC group) (p=0.92). Conclusion: Intracoronary bolus application of tirofiban was not associated with reduction in MACE rates compared to intravenous administration in patients with STEMI who underwent primary PCI. Future prospective trials with higher bolus doses of IC tirofiban should addressed to clarify this issue.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
- 2. Zijlstra F, Hoorntje JC, De Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-9.
- 3. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-85.
- 4. Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107:1840-3.
- 5. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GGL, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63.
- 6. Peerlinck K, De Lepeleire I, Goldberg M, Farrel D, Barrett J, Hand E, et al. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-7.
- 7. Lee DP, Herity NA, Hiat BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the Tırofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation 2003; 107: 1497-501.
- 8. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008; 72: 1605-9.
- 9. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Eng J Med 1985; 312: 932-6.
- 10. EPISTENT investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
- 11. Theroux P, Catella-Lawson F, Charbonnier B, Diodati J, Kouz S, Nasmith J, et al. for the PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
- 12. Topol E, Califf R, Simoons M, Diaz R, Paolasso E, Klein W, et al. for the PURSUIT Study Group. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebocontrolled, clinical trial. N Engl J Med 1998; 339: 436-43.
- 13. Brener S, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. For the RAPPORT Investigators. Randomized, placebo-controlled trial of glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-41.
- 14. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Grifin JJ, et al. For the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
- 15. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY Randomized Trial. JAMA 2008; 299: 1788-99.
- 16. Marzocchi A, Manari A, Piovaccari G, Marrozzini C, Marra S, Magnavacchi P, et al. For the FATA investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008; 29: 2972-80.
- 17. Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, et al. For the FATA investigators. Left ventricular function after ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the facilitated angioplasty with tirofiban or abciximab [FATA] trial). Am J Cardiol 2009; 103: 785-90.
- 18. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST segment elevation myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 2009; 53: 1668-73.
- 19. Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005; 105: 250-5.
- 20. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004; 62: 186-92.
- 21. Wöhrle J, Nusser T, Mayer C, Kochs M, Hombach V. Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. Eurointervention 2007; 3: 465-9.
- 22. Yang TY, Chang ST, Chung CM, Cheng NJ. Restoration of normal coronary flow with tirofiban by intracoronary administration fo noreflow phenomenon after stent deployment. Int Heart J 2005; 46: 139-45.
- 23. Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler W. Troponin T concentration concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002; 87: 520-4.
- 24. Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006; 47: 951-61.
- 25. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91:334-6.
- 26. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high risk percutaneous coronary intervention. Am J Cardiol 2006; 97: 489-93.
- 27. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 1187-93.
| APA | ERDİM R, ERCİYES D, Görmez S, karabay k, ÇATAKOĞLU A, AYTEKİN V, DEMİROĞLU C, GÜLBARAN M (2010). Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. , 340 - 345. |
| Chicago | ERDİM Refik,ERCİYES Demet,Görmez Selçuk,karabay kanber ocal,ÇATAKOĞLU Alp Burak,AYTEKİN Vedat,DEMİROĞLU Cemşid,GÜLBARAN Murat Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. (2010): 340 - 345. |
| MLA | ERDİM Refik,ERCİYES Demet,Görmez Selçuk,karabay kanber ocal,ÇATAKOĞLU Alp Burak,AYTEKİN Vedat,DEMİROĞLU Cemşid,GÜLBARAN Murat Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. , 2010, ss.340 - 345. |
| AMA | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. . 2010; 340 - 345. |
| Vancouver | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. . 2010; 340 - 345. |
| IEEE | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M "Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention." , ss.340 - 345, 2010. |
| ISNAD | ERDİM, Refik vd. "Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention". (2010), 340-345. |
| APA | ERDİM R, ERCİYES D, Görmez S, karabay k, ÇATAKOĞLU A, AYTEKİN V, DEMİROĞLU C, GÜLBARAN M (2010). Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyoloji Dergisi, 10(4), 340 - 345. |
| Chicago | ERDİM Refik,ERCİYES Demet,Görmez Selçuk,karabay kanber ocal,ÇATAKOĞLU Alp Burak,AYTEKİN Vedat,DEMİROĞLU Cemşid,GÜLBARAN Murat Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyoloji Dergisi 10, no.4 (2010): 340 - 345. |
| MLA | ERDİM Refik,ERCİYES Demet,Görmez Selçuk,karabay kanber ocal,ÇATAKOĞLU Alp Burak,AYTEKİN Vedat,DEMİROĞLU Cemşid,GÜLBARAN Murat Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyoloji Dergisi, vol.10, no.4, 2010, ss.340 - 345. |
| AMA | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyoloji Dergisi. 2010; 10(4): 340 - 345. |
| Vancouver | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyoloji Dergisi. 2010; 10(4): 340 - 345. |
| IEEE | ERDİM R,ERCİYES D,Görmez S,karabay k,ÇATAKOĞLU A,AYTEKİN V,DEMİROĞLU C,GÜLBARAN M "Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention." Anadolu Kardiyoloji Dergisi, 10, ss.340 - 345, 2010. |
| ISNAD | ERDİM, Refik vd. "Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention". Anadolu Kardiyoloji Dergisi 10/4 (2010), 340-345. |
